文献速递心血管CT

CT细胞外容积分数预测心脏淀粉样变性长期预后

Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2022-10-19

本研究纳入72例系统性淀粉样变性患者,采用心电门控心脏CT测量细胞外容积分数(ECVCT),比较不同心脏浸润程度下的ECVCT并与心肌重构及全因死亡率关联。结果示ECVCT与左室质量指数、LVEF、NT-proBNP及hs-TnT相关,且仅在ATTR淀粉样变中独立预测全因死亡(HR 1.046,95%CI 1.003-1.090,P=0.037)。

要点

  • ECVCT可在无法行心脏磁共振的患者中量化心肌细胞外间隙扩大。
  • ATTR型淀粉样变患者室间隔ECVCT独立预测全因死亡,AL型未显示独立关联。
  • ECVCT与左室重构、心功能及心肌损伤标志物相关,支持其作为风险分层工具。

核心结论

  • CT测量的心脏淀粉样变负荷与不良心肌重构及ATTR型患者全因死亡率相关。
  • ECVCT可能为淀粉样变患者提供更易获得的识别和风险分层手段。

研究设计与样本

  • 单中心研究,纳入72例确诊系统性淀粉样变患者(AL 35例,ATTR 37例),中位年龄67岁,男性70.8%。
  • 所有患者行心电门控心脏CT测量全心和室间隔ECVCT,并接受临床评估、心电图、超声心动图、血清淀粉样蛋白成分和/或99mTc-DPD闪烁显像。
  • 按ATTR Perugini分级和AL Mayo分期比较ECVCT,随访平均5.3±2.4年评估全因死亡。

关键影像表现/征象

  • AL型室间隔ECVCT均值42.7%±13.1%,ATTR型55.8%±10.9%。
  • ECVCT随AL和ATTR心脏淀粉样浸润程度增加而升高。
  • ECVCT与左室质量指数(r=0.426,P<0.001)、左室射血分数(r=0.460,P<0.001)、NT-proBNP(r=0.563,P<0.001)及高敏肌钙蛋白T(r=0.546,P<0.001)相关。

诊断标准与关键数值

  • 室间隔ECVCT在ATTR型中经年龄和室间隔壁厚度调整后独立与全因死亡相关(HR 1.046,95%CI 1.003-1.090,P=0.037)。
  • AL型中室间隔ECVCT与全因死亡无独立关联。

临床应用与阅片要点

  • 对于有心脏装置或透析等不适合心脏磁共振的患者,可考虑用CT测量ECVCT评估心肌淀粉样变负荷。
  • ATTR型患者室间隔ECVCT升高提示死亡风险增加,可辅助风险分层。
  • ECVCT与左室质量指数、LVEF、NT-proBNP及hs-TnT相关,阅片时可结合这些指标综合判断。

局限性

  • 单中心研究,样本量较小(72例)。
  • 随访期间死亡40例(AL 14例,ATTR 26例),事件数有限。
  • ECVCT仅在ATTR型中独立预测死亡,AL型未见独立关联,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Light chain (AL) and transthyretin (ATTR) amyloid fibrils are deposited in the extracellular space of the myocardium, resulting in heart failure and premature mortality. Extracellular expansion can be quantified by computed tomography, offering a rapid, cheaper, and more practical alternative to cardiac magnetic resonance, especially among patients with cardiac devices or on renal dialysis.

OBJECTIVES: This study sought to investigate the association of extracellular volume fraction by computed tomography (ECVCT), myocardial remodeling, and mortality in patients with systemic amyloidosis.

METHODS: Patients with confirmed systemic amyloidosis and varying degrees of cardiac involvement underwent electrocardiography-gated cardiac computed tomography. Whole heart and septal ECVCT was analyzed. All patients also underwent clinical assessment, electrocardiography, echocardiography, serum amyloid protein component, and/or technetium-99m (99mTc) 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. ECVCT was compared across different extents of cardiac infiltration (ATTR Perugini grade/AL Mayo stage) and evaluated for its association with myocardial remodeling and all-cause mortality.

RESULTS: A total of 72 patients were studied (AL: n = 35, ATTR: n = 37; median age: 67 [IQR: 59-76] years, 70.8% male). Mean septal ECVCT was 42.7% ± 13.1% and 55.8% ± 10.9% in AL and ATTR amyloidosis, respectively, and correlated with indexed left ventricular mass (r = 0.426; P < 0.001), left ventricular ejection fraction (r = 0.460; P < 0.001), N-terminal pro-B-type natriuretic peptide (r = 0.563; P < 0.001), and high-sensitivity troponin T (r = 0.546; P < 0.001). ECVCT increased with cardiac amyloid involvement in both AL and ATTR amyloid. Over a mean follow-up of 5.3 ± 2.4 years, 40 deaths occurred (AL: n = 14 [35.0%]; ATTR: n = 26 [65.0%]). Septal ECVCT was independently associated with all-cause mortality in ATTR (not AL) amyloid after adjustment for age and septal wall thickness (HR: 1.046; 95% CI: 1.003-1.090; P = 0.037).

CONCLUSIONS: Cardiac amyloid burden quantified by ECVCT is associated with adverse cardiac remodeling as well as all-cause mortality among ATTR amyloid patients. ECVCT may address the need for better identification and risk stratification of amyloid patients, using a widely accessible imaging modality.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Gama, Rosmini, Bandula, et al. Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022. PMID: 36274040. doi:10.1016/j.jcmg.2022.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。